Evidence map›Paper›PMID 33414379›Full record

ArticleTranslational psychiatry2021

Biallelic mutations in the death domain of PIDD1 impair caspase-2 activation and are associated with intellectual disability.

Taimoor I Sheikh, Nasim Vasli, Stephen Pastore, Kimia Kharizi, Ricardo Harripaul, Zohreh Fattahi, Shruti Pande, Farooq Naeem, Abrar Hussain, Asif Mir and 12 more

Open access · goldAbstract read
In one paragraph

Article in Translational psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
8.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 148 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. HeterozygousGenes · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 5 countries.

Taimoor I SheikhMolecular Neuropsychiatry & Development (MiND) Lab, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, M5T 1R8, Canada.
Nasim VasliMolecular Neuropsychiatry & Development (MiND) Lab, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, M5T 1R8, Canada.
Stephen PastoreMolecular Neuropsychiatry & Development (MiND) Lab, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, M5T 1R8, Canada.
Kimia KhariziGenetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, 19834, Iran.
Ricardo HarripaulMolecular Neuropsychiatry & Development (MiND) Lab, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, M5T 1R8, Canada.
Zohreh FattahiGenetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, 19834, Iran.
Shruti PandeDepartment of Medical Genetics, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.
Farooq NaeemGeneral and Health Systems Psychiatry, Centre for Addiction and Mental Health, Toronto, ON, M5T 1R8, Canada.
Abrar HussainHuman Molecular Genetics Lab, Department of Biological Sciences, FBAS, International Islamic University, Islamabad, Pakistan.
Asif MirHuman Molecular Genetics Lab, Department of Biological Sciences, FBAS, International Islamic University, Islamabad, Pakistan.
Omar IslamDepartment of Diagnostic Radiology, Queens University, Kingston, ON, K7L 2V7, Canada.ORCID 0000-0002-3222-9374
Katta Mohan GirishaDepartment of Medical Genetics, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.ORCID 0000-0002-0139-8239
Muhammad IrfanDepartment of Mental Health, Psychiatry and Behavioural Sciences, Peshawar Medical College, Riphah International University, Islamabad, Pakistan.
Muhammad AyubLahore Institute of Research & Development, Lahore, 51000, Pakistan.
Christoph SchwarzerDepartment of Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.
Hossein NajmabadiGenetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, 19834, Iran.
Anju ShuklaDepartment of Medical Genetics, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.
Valentina C SladkyInstitute for Developmental Immunology, Biocenter Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0002-2973-3174
Vincent Zoran BraunInstitute for Developmental Immunology, Biocenter Medical University of Innsbruck, Innsbruck, Austria.
Irmina Garcia-CarpioInstitute for Developmental Immunology, Biocenter Medical University of Innsbruck, Innsbruck, Austria.
Andreas VillungerInstitute for Developmental Immunology, Biocenter Medical University of Innsbruck, Innsbruck, Austria. andreas.villunger@i-med.ac.at.
John B VincentMolecular Neuropsychiatry & Development (MiND) Lab, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, M5T 1R8, Canada. john.vincent@camh.ca.ORCID 0000-0003-0692-2519
Centre for Addiction and Mental Health · CAInnsbruck Medical University · ATManipal Academy of Higher Education · INInternational Islamic University, Islamabad · PKQueen's University · CAUniversity of Social Welfare and Rehabilitation Sciences · IRHospital Labbafinejad · IRRiphah International University · PK

Funding

Genetic Diagnosis of Neurodevelopmental Disorders in IndiaR01HD093570 · NICHD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BIELAS, STEPHANIE LEE · 2018 to 2024
$2.3M
Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) FWF (PIR-3)Brain and Behavior Research Foundation (Brain & Behavior Research Foundation) n/aEC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) POLICEGouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) MOP-102758Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) PJT-156402Iran National Science Foundation (INSF) 920384578NICHD NIH HHS R01 HD093570U.S. Department of Health & Human Services | NIH | Center for Information Technology (Center for Information Technology, National Institutes of Health) 1R01HD093570-01A1
6 · The paper itself

Abstract

PIDD1 encodes p53-Induced Death Domain protein 1, which acts as a sensor surveilling centrosome numbers and p53 activity in mammalian cells. Early results also suggest a role in DNA damage response where PIDD1 may act as a cell-fate switch, through interaction with RIP1 and NEMO/IKKg, activating NF-κB signaling for survival, or as an apoptosis-inducing protein by activating caspase-2. Biallelic truncating mutations in CRADD-the protein bridging PIDD1 and caspase-2-have been reported in intellectual disability (ID), and in a form of lissencephaly. Here, we identified five families with ID from Iran, Pakistan, and India, with four different biallelic mutations in PIDD1, all disrupting the Death Domain (DD), through which PIDD1 interacts with CRADD or RIP1. Nonsense mutations Gln863* and Arg637* directly disrupt the DD, as does a missense mutation, Arg815Trp. A homozygous splice mutation in the fifth family is predicted to disrupt splicing upstream of the DD, as confirmed using an exon trap. In HEK293 cells, we show that both Gln863* and Arg815Trp mutants fail to co-localize with CRADD, leading to its aggregation and mis-localization, and fail to co-precipitate CRADD. Using genome-edited cell lines, we show that these three PIDD1 mutations all cause loss of PIDDosome function. Pidd1 null mice show decreased anxiety, but no motor abnormalities. Together this indicates that PIDD1 mutations in humans may cause ID (and possibly lissencephaly) either through gain of function or secondarily, due to altered scaffolding properties, while complete loss of PIDD1, as modeled in mice, may be well tolerated or is compensated for.

Indexed as

CRADD Signaling Adaptor ProteinIntellectual DisabilityAnimalsCaspase 2Death DomainDeath Domain Receptor Signaling Adaptor ProteinsHEK293 CellsHumansIndiaMiceMutationCaspase 2CRADD Signaling Adaptor ProteinDeath Domain Receptor Signaling Adaptor ProteinsPIDD1 protein, humanPidd1 protein, mouse

Identifiers

PMID33414379
PMCPMC7791037
OpenAlexW3120487758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.